FOXC1: a therapeutic biomarker specific for basal-like breast cancer, is not only a potential prognostic candidate but also a potential molecular therapeutic target for this subtype of breast cancer [37, 38]. This evidence concerns the gene FOXC1 and breast carcinoma.